Search the Newsreel

JAZZ Looks 68.1% Overvalued on GF Value™

Jazz Pharmaceuticals (NASDAQ: JAZZ) is scheduled to report its second-quarter earnings on August 3rd, amidst an elevated Price-to-Sales ratio of 3.55, suggesting it is 68.1% overvalued according to its GF Value™. Despite a strong GF Score of 73 highlighting profitability and growth, concerns are …

Precision Trading with Jazz Pharmaceuticals Plc (JAZZ) Risk Zones

This article provides a precision trading analysis for Jazz Pharmaceuticals Plc (JAZZ), highlighting strong sentiment across all horizons and tested resistance levels. It outlines specific institutional trading strategies, including long, breakout, and short setups with defined entry, target, and stop-loss zones. The analysis is …

Jazz Pharmaceuticals PLC (JAZZ) Financial Health: Profitability & Balance Sheet Analysis

Jazz Pharmaceuticals PLC (JAZZ) has a stable financial score of 8.58, ranking 40th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 19.05% year-over-year revenue increase to $1.07 billion and a remarkable 416.72% increase in net profit. …

Should Anticipated Earnings Beat and Employer Award Recognition Require Action From Jazz Pharmaceuticals (JAZZ) Investors?

Jazz Pharmaceuticals (JAZZ) is projected to report a significant year-over-year earnings increase for Q2 2026 and recently received a Gold Stevie Award for Employer of the Year, indicating strong operational performance and a positive workplace culture. While these factors boost near-term confidence, investors should …

Jazz Pharmaceuticals (JAZZ) Projected to Announce Earnings on Monday

Jazz Pharmaceuticals (JAZZ) is expected to report its Q2 2026 earnings after market close on Monday, August 3rd, with analysts projecting $6.18 EPS and $1.114 billion in revenue. The company's stock has risen, trading near its 12-month high with a "Moderate Buy" consensus from …

Jazz Pharmaceuticals PLC (JAZZ) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Jazz Pharmaceuticals PLC (JAZZ) stock performance, showing a closing price of $255.440 and a market cap of $15.69 billion. It notes that the company has not distributed any dividends over the past five years. The page also includes current …

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

TradingKey

This article provides a detailed cash flow statement for Jazz Pharmaceuticals PLC (JAZZ) across numerous quarters and fiscal years. It includes operating, investing, and financing cash flows, along with related financial metrics like capital expenditures and free cash flow. The data is presented with …

Jazz Pharmaceuticals (JAZZ) Stock Still Looks Cheap As Shares Jumped 115%

Jazz Pharmaceuticals (JAZZ) stock has seen a significant 115% jump over the past year, yet Simply Wall St's valuation checks present a mixed picture, suggesting it's not a clear bargain or clearly overvalued. While the company screens as undervalued on 4 of 6 measures …

Jazz Pharmaceuticals plc Revenue Breakdown – NASDAQ:JAZZ

Jazz Pharmaceuticals plc generated $4.27 billion USD last year, primarily from its Pharmaceutical Products segment. This represents an increase from $4.07 billion USD in the previous year. The United States was the largest contributor to revenue, accounting for $3.83 billion USD.

JAZZ|Jazz Pharmaceuticals PLC|Price:253.870|Chg%:-1.000

Jazz Pharmaceuticals PLC is currently trading at $253.870, experiencing a slight decrease of 0.39%. Despite a recent turnaround to a loss and institutional selling, the company's fundamentals are considered healthy with high growth potential, and it is currently rated as a "Buy" by analysts …

Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Aristotle Capital Management LLC

Aristotle Capital Management LLC decreased its stake in Jazz Pharmaceuticals PLC by 17.8% in Q1 2026, selling over 28,000 shares. Despite this, other institutional investors like Franklin Resources Inc., Bank of New York Mellon Corp, and Adage Capital Partners GP L.L.C. significantly increased their …

Jazz Pharmaceuticals Reports Outcomes of 2026 Annual General Meeting with Strong Shareholder Backing

Jazz Pharmaceuticals plc held its 2026 Annual General Meeting where shareholders showed strong support for key proposals, including board nominations and the appointment of auditors. This outcome suggests continued investor confidence in the company's governance and strategic direction. The article, however, requires login to …

Jazz Pharmaceuticals (NASDAQ: JAZZ) posts full 2026 AGM voting results

Jazz Pharmaceuticals plc announced the results of its 2026 annual general meeting held in Dublin. Shareholders approved the election of three directors, the appointment of KPMG, Dublin as independent auditors, and the compensation of named executive officers on a non-binding basis. Additionally, shareholders granted …

Jazz Pharmaceuticals PLC $JAZZ is Systematic Financial Management LP's 5th Largest Position

Systematic Financial Management LP increased its stake in Jazz Pharmaceuticals PLC (JAZZ) by 2.6% in Q1, making it their 5th largest position. Institutional ownership of JAZZ is very high at 89.14%, with several major investors recently boosting their holdings. Wall Street sentiment for Jazz …

Jazz Pharmaceuticals’ 43-week Trend Signal approaches its high as volume thins

JAZZ closed just 1.2% below its 52-week high after a 26.0% quarter, but the latest advance came on only 0.7x normal volume and activity pressure has cooled from June levels.

Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com

Jazz Pharmaceuticals PLC stock has reached an all-time high at $250.85, reflecting a significant 1-year change of 114.77% and a market capitalization of $15.71 billion. Despite this, InvestingPro analysis suggests the company is undervalued relative to its fair value, boasting impressive gross profit margins …

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

Jazz Pharmaceuticals sets Aug. 3 webcast after market close

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to review results and provide a business and …

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Jazz Pharmaceuticals plc announced it will report its second-quarter 2026 financial results on Monday, August 3, 2026, after the close of U.S. financial markets. The company's management will host a webcast at 4:30 p.m. ET to discuss the results and provide business and financial …

Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative?

Jazz Pharmaceuticals' investment narrative is gaining fresh attention from investors who are re-evaluating its sleep-disorder and oncology portfolios. The focus is on the company's pipeline progress, particularly with AXS-12's FDA filing and its broader sleep-disorder franchise, alongside its push into targeted rare cancer therapies. …

Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary

Jazz Pharmaceuticals (JAZZ) reported record Q1 2026 revenues of $1.1 billion, a 19% year-over-year increase, driven by strong growth in its sleep, epilepsy, and oncology portfolios. The company achieved a net income of $293.1 million, a significant improvement from a Q1 2025 net loss, …

Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run

Jazz Pharmaceuticals (JAZZ) has seen a significant 119.3% return over the past year, prompting an evaluation of its current valuation. Despite this strong performance, Simply Wall St's analysis suggests the stock appears undervalued on several measures, trading at a P/S ratio (3.5x) below its …

Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?

Jazz Pharmaceuticals (JAZZ) Proxy filing Summary

Jazz Pharmaceuticals (JAZZ) has released its proxy filing summary for an annual general meeting (AGM) scheduled for July 23, 2026. Shareholders of record by May 28, 2026, are eligible to vote on director nominees and five other proposals, with the board recommending a "FOR" …

JAZZ PHARMACEUTICALS PLC : CANACCORD GENUITY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $290

Canaccord Genuity has initiated coverage on Jazz Pharmaceuticals PLC (JAZZ.O) with a "BUY" rating. The firm has set a target price of $290 for the company's shares. This report originated from Reuters and was published on July 17, 2026, at 04:40.

Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story?

Jazz Pharmaceuticals (JAZZ) has shown strong share price performance and revenue growth, leading to a narrative that pegs it as 7.4% undervalued with a fair value of $257.00. This optimism stems from the expected approval and launch of new therapies, particularly within its oncology …

Jazz Pharmaceuticals loses short-term rank while its 39-week Trend Signal stays intact

JAZZ has cooled from a near-high run, with volume and Market Dynamics no longer confirming the earlier advance even as the weekly trend remains constructive.